Psoriatic arthritis: Epidemiology, diagnosis, and treatment

Abstract

Our understanding of psoriatic arthritis has evolved as new knowledge of the disease has emerged. However, the exact prevalence of psoriatic arthritis is unknown, and its pathogenesis has not been fully elucidated. Genetic, environmental, and immunologic factors have all been implicated in disease development. Early diagnosis and treatment have become primary objectives in clinical rheumatology. Psoriatic arthritis not only causes functional impairment, but also increases mortality risk of patients. The advent of new therapeutic agents capable of arresting the progression of joint damage is expected. However, early psoriatic arthritis assessment remains limited. The objectives of this article are to outline the epidemiology, diagnosis, and treatment of psoriatic arthritis and to suggest a paradigm for identifying early psoriatic arthritis patients.

Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registry

“…PsA is manifested in a diverse range of symptoms, and symptom severity varies over time, which complicates treatment and may influence treatment persistence [15,16]. Factors associated with persistence differ based on prior biologic experience.…”

Untitled

“…Psoriatic arthritis (PsA) is a chronic disease that induces inflammation of the synovial tissue, entheses, and skin [1]. The afflicted subjects have heterogeneous clinical presentations that include diverse articular and dermatological traits, as well as joint and spine complications [1,2].…”

“…The afflicted subjects have heterogeneous clinical presentations that include diverse articular and dermatological traits, as well as joint and spine complications [1,2]. The comorbidities that impact individuals with PsA include cardiovascular disease, hypercholesterolemia, obesity, hypertension, type 2 diabetes mellitus, anxiety and/or depression, and kidney disease [3].…”

“…The comorbidities that impact individuals with PsA include cardiovascular disease, hypercholesterolemia, obesity, hypertension, type 2 diabetes mellitus, anxiety and/or depression, and kidney disease [3]. The subjects also suffer from increased mortality, along with declines in their quality of life [1].…”

“…There are several treatment options for PsA available and others currently in clinical trials, including nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), anti-tumor necrosis factor (TNF), anti-interleukin (IL)-17, anti-IL-12/IL-23 and anti-T cell activation medications [1] (Table 1). However, each of the current treatment options has certain limitations.…”